Market Cap 160.64M
Revenue (ttm) 0.00
Net Income (ttm) -41.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,455,900
Avg Vol 1,239,212
Day's Range N/A - N/A
Shares Out 84.99M
Stochastic %K 11%
Beta 0.61
Analysts Sell
Price Target $3.50

Company Profile

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collabora...

Industry: Biotechnology
Sector: Healthcare
Phone: 514-336-0444
Address:
1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, Canada
Tonyboner
Tonyboner Oct. 25 at 5:15 PM
$MIST In July 2025, Milestone Pharmaceuticals issued a total of 73,504,670 common warrants in a public offering. This consisted of two distinct series of warrants sold as part of a single package with common shares or pre-funded warrants. Here is the breakdown of the warrants issued: Series A Common Warrants: 35,002,335 warrants. Series B Common Warrants: 35,002,335 warrants. Pre-funded Warrants: 3,502,335 warrants.
0 · Reply
Porki
Porki Oct. 25 at 2:41 PM
$MIST this is insightful. Comparing this to FBIO’s- the run started a little more than a month before but the biggest run began the month of.
0 · Reply
Porki
Porki Oct. 25 at 2:03 PM
$MIST per the 10Q We expect that our operating plan, existing cash and cash equivalents and short-term investments, including the proceeds from the July 11, 2025 offering discussed below, to be sufficient to fund our operations for at least the next 12 months from the date of issuance of this Form 10-Q for the quarter ending June 30, 2025. To add the didn’t sell from the ATM for the first 6mo out of the year. The warrants are a concern, but interestingly the price is hovering at 1.88 - where the series b warrants are priced at 1.875. Even though the series A are priced at 1.50 id be shocked if they just “take the easy money” considering FDA news and 75mil additional funding upon successful completion is along the way.
2 · Reply
Tonyboner
Tonyboner Oct. 24 at 8:18 PM
$MIST You know what really gets me is morons who sit and pump the BS, and they do not even know how to read a 10q I'm long on this dog, but the facts are millions of shares are prob getting converted, I want the SP to go up, but you are fighting guys who are making millions by selling, the OS once converted is 220 million shares, I'm just stating facts and anyone can find the information, just look for it.
1 · Reply
Pullup3
Pullup3 Oct. 24 at 8:00 PM
$MIST what’s the price target for this?
1 · Reply
Stockseeking
Stockseeking Oct. 24 at 6:25 PM
$MIST above average volume is a positive sign leading to the last week of Oct. Will see some real actions starting in Nov with one month till PDUFA.
1 · Reply
Tonyboner
Tonyboner Oct. 24 at 6:17 PM
$MIST No reason for this to be down except dilution is going on, most biotech is ramping up
1 · Reply
Diverstj981
Diverstj981 Oct. 24 at 5:51 PM
$MIST Get rich or die tryin'. Added 5k. Now 60k total. Mgmt better not fuc# this up AGAIN.
1 · Reply
danw1978
danw1978 Oct. 24 at 3:40 PM
$MIST All part of the cycle, at least according to ChatGPT
1 · Reply
Syndr78
Syndr78 Oct. 24 at 3:32 PM
$MIST This will be taken down to the 1.70s, or even 1.60s before December. Sadly.
4 · Reply
Latest News on MIST
Milestone® Pharmaceuticals to Present at Upcoming Conferences

Aug 19, 2025, 8:00 AM EDT - 2 months ago

Milestone® Pharmaceuticals to Present at Upcoming Conferences


Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge

Jul 11, 2025, 2:37 PM EDT - 3 months ago

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge


Milestone Pharmaceuticals Announces Proposed Public Offering

Jul 11, 2025, 6:01 AM EDT - 3 months ago

Milestone Pharmaceuticals Announces Proposed Public Offering


FDA Issues Complete Response Letter for Etripamil for PSVT

Mar 28, 2025, 7:00 AM EDT - 7 months ago

FDA Issues Complete Response Letter for Etripamil for PSVT


Tonyboner
Tonyboner Oct. 25 at 5:15 PM
$MIST In July 2025, Milestone Pharmaceuticals issued a total of 73,504,670 common warrants in a public offering. This consisted of two distinct series of warrants sold as part of a single package with common shares or pre-funded warrants. Here is the breakdown of the warrants issued: Series A Common Warrants: 35,002,335 warrants. Series B Common Warrants: 35,002,335 warrants. Pre-funded Warrants: 3,502,335 warrants.
0 · Reply
Porki
Porki Oct. 25 at 2:41 PM
$MIST this is insightful. Comparing this to FBIO’s- the run started a little more than a month before but the biggest run began the month of.
0 · Reply
Porki
Porki Oct. 25 at 2:03 PM
$MIST per the 10Q We expect that our operating plan, existing cash and cash equivalents and short-term investments, including the proceeds from the July 11, 2025 offering discussed below, to be sufficient to fund our operations for at least the next 12 months from the date of issuance of this Form 10-Q for the quarter ending June 30, 2025. To add the didn’t sell from the ATM for the first 6mo out of the year. The warrants are a concern, but interestingly the price is hovering at 1.88 - where the series b warrants are priced at 1.875. Even though the series A are priced at 1.50 id be shocked if they just “take the easy money” considering FDA news and 75mil additional funding upon successful completion is along the way.
2 · Reply
Tonyboner
Tonyboner Oct. 24 at 8:18 PM
$MIST You know what really gets me is morons who sit and pump the BS, and they do not even know how to read a 10q I'm long on this dog, but the facts are millions of shares are prob getting converted, I want the SP to go up, but you are fighting guys who are making millions by selling, the OS once converted is 220 million shares, I'm just stating facts and anyone can find the information, just look for it.
1 · Reply
Pullup3
Pullup3 Oct. 24 at 8:00 PM
$MIST what’s the price target for this?
1 · Reply
Stockseeking
Stockseeking Oct. 24 at 6:25 PM
$MIST above average volume is a positive sign leading to the last week of Oct. Will see some real actions starting in Nov with one month till PDUFA.
1 · Reply
Tonyboner
Tonyboner Oct. 24 at 6:17 PM
$MIST No reason for this to be down except dilution is going on, most biotech is ramping up
1 · Reply
Diverstj981
Diverstj981 Oct. 24 at 5:51 PM
$MIST Get rich or die tryin'. Added 5k. Now 60k total. Mgmt better not fuc# this up AGAIN.
1 · Reply
danw1978
danw1978 Oct. 24 at 3:40 PM
$MIST All part of the cycle, at least according to ChatGPT
1 · Reply
Syndr78
Syndr78 Oct. 24 at 3:32 PM
$MIST This will be taken down to the 1.70s, or even 1.60s before December. Sadly.
4 · Reply
Acemaker12
Acemaker12 Oct. 24 at 2:37 PM
$MIST With no existing sales force in place, it seems much more likely they get BO post approval. Most companies hire prior to launch so reps are trained and ready to go. Surely someone already in the EP cardiology space is already looking at them.
2 · Reply
Acemaker12
Acemaker12 Oct. 24 at 2:10 PM
$MIST Added 8,500 shares this week
0 · Reply
momoinvestor
momoinvestor Oct. 24 at 2:10 PM
$MIST Can't imagine selling now when the pay-off is just around the corner in Dec... simply a waiting game.
0 · Reply
Tonyboner
Tonyboner Oct. 24 at 1:48 PM
$MIST Definitely warrant selling here imo
1 · Reply
CashisKing_
CashisKing_ Oct. 24 at 11:01 AM
0 · Reply
TheGreedyGrench
TheGreedyGrench Oct. 23 at 11:43 PM
$MIST Business as usual.. XBI green and MIST red 👍🏻
1 · Reply
Elegant_Confusion
Elegant_Confusion Oct. 23 at 10:51 PM
$MIST “Ongoing reviews of drug applications already under FDA review will proceed, funded by FY2024 user fees. However, communication from regulators may be slower than usual. Routine research, policy development, and most surveillance inspections are paused until appropriations resume.” “A major limitation is that FDA cannot collect new FY 2026 user fees until Congress passes an appropriation. For example, FDA recently confirmed that the Generic Drug User Fee Amendments (GDUFA) system is deactivated until funding is restored. By law, these fees are not due until either October 1 or the first business day after appropriations are enacted—whichever is later.” “This means no GDUFA or PDUFA annual fees are payable until the shutdown ends. However, new submissions requiring user fees (NDAs, BLAs, ANDAs, biosimilars) cannot be accepted during this period. Applications filed electronically will sit in queue until the government reopens.”
1 · Reply
OGLUCIDBULL
OGLUCIDBULL Oct. 23 at 5:40 PM
$MIST quite the daily. I love the greedygrenches diarrhea mouth posts.
0 · Reply
Tonyboner
Tonyboner Oct. 23 at 5:27 PM
$MIST It's prob down because of the stupid deal the CEO with the $1.50 warrants 😡
3 · Reply
TheGreedyGrench
TheGreedyGrench Oct. 23 at 4:38 PM
$MIST We still buying those dips while the smart money is shorting them LoL
0 · Reply
OGLUCIDBULL
OGLUCIDBULL Oct. 23 at 4:27 PM
$MIST I wonder who’s assigned to short this. They’re on it all day since 2.3 fashioning the chart into a descending pattern. Recycling the same shorts getting 1-2m vol per day.
1 · Reply
Stockseeking
Stockseeking Oct. 23 at 4:19 PM
$MIST tightly controlled with small volumes, be patient, Dec 13 is in less than 2 months, then celebrate for a 2x
0 · Reply